Rhabdomyosarcoma

RMS Primer - Tiny Tumors

• Definition: A malignant mesenchymal tumor characterized by rhabdomyoblastic differentiation (cells resembling striated muscle).
• Epidemiology: The most common soft tissue sarcoma in children.
• Peak Incidence: Bimodal distribution, with peaks at 2-6 years and 14-18 years.
• Associated Syndromes: Li-Fraumeni syndrome, NF1, Beckwith-Wiedemann syndrome, Costello syndrome.

⭐ Rhabdomyosarcoma is the most common soft tissue sarcoma in children.

RMS Patho & Types - Cellular Culprits

• Origin: Primitive mesenchymal cells (skeletal muscle lineage).
• Histological Subtypes:
  • Embryonal (ERMS): ~60-70%, better prognosis. Variants: Botryoid (best prognosis), Spindle cell (includes Sclerosing RMS).
  • Alveolar (ARMS): ~20-30%, worse prognosis. Translocations: t(2;13) PAX3-FOXO1 (commoner, poorer), t(1;13) PAX7-FOXO1.
  • Pleomorphic: Rare in children.

⭐ Alveolar RMS: PAX-FOXO1 fusions; t(2;13) PAX3-FOXO1 (common, aggressive). oka

RMS Sites & Signs - Location Clues

Presentation: Often painless mass; varies by site.

Favorable Sites:

• Orbit: Proptosis, diplopia.
• Non-parameningeal Head & Neck (H&N): Painless mass.
• GU (non-Bladder/Prostate): Paratesticular, vaginal, uterine masses.

Unfavorable Sites:

• Parameningeal H&N (nasopharynx, middle ear, paranasal sinuses): Cranial nerve palsies, proptosis; CSF spread risk.
• Bladder/Prostate: Hematuria, obstruction.
• Extremities/Trunk: Swelling, pain.

⭐ Sarcoma botryoides (embryonal RMS variant): grape-like mass in vagina/bladder.

oka

RMS Diagnosis & Staging - Pinpointing the Foe

• Biopsy: Essential (incisional/excisional/core). Histopathology + IHC.
• IHC Markers: Desmin, Myogenin (Myf4), MyoD1 (Myf3) - highly specific.
• Imaging:
  • Primary: MRI (preferred), CT.
  • Metastasis: CT Chest, PET-CT, Bone scan.
• Staging Workup: Bone marrow aspiration & biopsy. CSF cytology (parameningeal).
• Staging Systems: IRS Clinical Group (I-IV), TNM Pre-treatment.

  ⭐ Myogenin and MyoD1 are nuclear transcription factors crucial for myogenic differentiation and are highly specific immunohistochemical markers for RMS.

RMS Treatment - Multimodal Attack

• Standard: Aggressive multimodal therapy (Chemotherapy, Surgery, Radiotherapy).
• Risk-adapted strategy guides intensity: Low, Intermediate, High-risk groups.
• Chemotherapy:
  • Core: VAC (Vincristine, Actinomycin D, Cyclophosphamide) or IVA.
  • High-risk: Dose intensification.
• Surgery: Wide local excision aiming for negative margins. Organ preservation is key.
• Radiotherapy (RT): Crucial for local control, especially if unresectable or positive margins. Proton therapy considered.

⭐ VAC (Vincristine, Actinomycin D, Cyclophosphamide) is the cornerstone chemotherapy regimen.

RMS Prognosis & Genetics - Future Outlook

• Overall survival: ~70-80%; varies by risk group.
• Key Prognostic Factors:
  • Histology: Embryonal (favorable) vs. Alveolar (unfavorable).
  • Site: Favorable (e.g., orbit) vs. Unfavorable.
  • Stage & IRS Group (resectability, extent).
  • Age: <1 yr or >10 yrs may have worse outcomes.
  • Response to initial therapy.
• Genetics:

  ⭐ PAX3-FOXO1 fusion (esp. in Alveolar RMS) = poor prognosis.

• Long-term sequelae: Growth impairment, endocrine dysfunction, secondary malignancies (↑ risk).

High‑Yield Points - ⚡ Biggest Takeaways

• Most common pediatric soft tissue sarcoma; bimodal age peak (2-6 yrs, teens).
• Key sites: Head & Neck (orbit, parameningeal), Genitourinary (sarcoma botryoides), Extremities.
• Embryonal (common, better prognosis) vs. Alveolar (aggressive, PAX-FOXO1 fusion).
• Histologically a "small round blue cell tumor".
• Multimodal therapy (surgery, chemotherapy, radiotherapy) is standard.
• Parameningeal sites: high CNS extension risk, mandating CNS evaluation.
• Prognosis: Alveolar histology worse; depends on site, stage, resectability.